Landsteiner Genmed and Vall d’Hebron Institute of Research Communicate Pioneering Preclinical Efficacy Data on the New Compound NPO-2270 in Heart Failure Models
NPO-2270 ameliorates cardiac dysfunction more effectively than enalapril in two experimental models of heart failure.